Compare Adaptive Biotechnologies Corp (ADPT) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Credo Technology Group Holding Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Credo Technology Group Holding Ltd trades at $264.75 (market cap $46.19B). The key difference: Credo Technology Group Holding Ltd is far larger — about 11.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | CRDO | |
|---|---|---|
Market Cap | $4.04B | $46.19B |
Sector | Health | Technology |
52-Week High | $25.45 | $302.52 |
52-Week Low | $12.30 | $87.81 |
Enterprise Value | $4.10B | $44.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
CRDO trades at $257.10, up 7.15% today, with strong bullish momentum supported by technical indicators and positive analyst sentiment. The stock shows robust fundamentals with 157% revenue growth in Q4 2025 and consistent earnings beats. Recent news highlights Credo's strategic positioning in AI infrastructure, including contributions to the Open Compute Project and institutional investment increases.
Outlook remains positive with 86.7% analyst buy ratings and a $285.42 consensus price target, though premium valuations (P/E 98.7) and recent insider selling warrant caution. Key risks include customer concentration and execution challenges in the competitive AI hardware space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
